Intensive Chemotherapy With or Without Gemtuzumab Ozogamicin for NPM1-Mutated AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial
Lancet Haematol 2023 May 12;[EPub Ahead of Print], H Döhner, D Weber, J Krzykalla, W Fiedler, MWM Kühn, T Schroeder, K Mayer, M Lübbert, M Wattad, K Götze, L Fransecky, E Koller, G Wulf, J Schleicher, M Ringhoffer, R Greil, B Hertenstein, J Krauter, UM Martens, D Nachbaur, MA Samra, S Machherndl-Spandl, N Basara, C Leis, A Schrade, S Kapp-Schwoerer, S Cocciardi, L Bullinger, F Thol, M Heuser, P Paschka, VI Gaidzik, M Saadati, A Benner, RF Schlenk, K Döhner, A GanserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.